Healthcare provider profile · identity verified

Corina Scheel Clark, P.A.

Physician Assistant · CASTRO VALLEY, CA · NPI 1720480049

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	647	300
Amlodipine Besylate	Amlodipine Besylate	350	180
Levothyroxine Sodium	Levothyroxine Sodium	344	157
Losartan Potassium	Losartan Potassium	316	139
Rosuvastatin Calcium	Rosuvastatin Calcium	257	120
Lisinopril	Lisinopril	245	122
Metoprolol Succinate	Metoprolol Succinate	203	94
Simvastatin	Simvastatin	182	80
Metformin Hcl	Metformin Hcl	180	86
Gabapentin	Gabapentin	168	81
Hydrochlorothiazide	Hydrochlorothiazide	146	70
Omeprazole	Omeprazole	143	65
Pantoprazole Sodium	Pantoprazole Sodium	137	65
Famotidine	Famotidine	106	49
Albuterol Sulfate Hfa	Albuterol Sulfate	103	54
Metoprolol Tartrate	Metoprolol Tartrate	103	47
Tamsulosin Hcl	Tamsulosin Hcl	103	49
Montelukast Sodium	Montelukast Sodium	100	39
Furosemide	Furosemide	97	44
Allopurinol	Allopurinol	95	41
Pravastatin Sodium	Pravastatin Sodium	92	40
Sertraline Hcl	Sertraline Hcl	92	42
Trazodone Hcl	Trazodone Hcl	87	43
Eliquis	Apixaban	85	32
Potassium Chloride	Potassium Chloride	79	31
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	78	35
Atenolol	Atenolol	75	36
Clopidogrel	Clopidogrel Bisulfate	69	35
Hydralazine Hcl	Hydralazine Hcl	68	36
Metformin Hcl Er	Metformin Hcl	65	31
Carvedilol	Carvedilol	62	32
Ozempic	Semaglutide	61	24
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	60	24
Breo Ellipta	Fluticasone/Vilanterol	59	15
Escitalopram Oxalate	Escitalopram Oxalate	57	23
Ezetimibe	Ezetimibe	57	21
Ibuprofen	Ibuprofen	55	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	55	27
Fluticasone Propionate	Fluticasone Propionate	53	30
Alendronate Sodium	Alendronate Sodium	52	31
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	47	34
Donepezil Hcl	Donepezil Hcl	45	16
Glipizide Er	Glipizide	45	24
Lovastatin	Lovastatin	45	23
Duloxetine Hcl	Duloxetine Hcl	43	15
Mirtazapine	Mirtazapine	43	18
Finasteride	Finasteride	41	18
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	41	17
Fluoxetine Hcl	Fluoxetine Hcl	39	16
Triamcinolone Acetonide	Triamcinolone Acetonide	38	24
Citalopram Hbr	Citalopram Hydrobromide	36	16
Meloxicam	Meloxicam	36	21
Glipizide	Glipizide	35	18
Synthroid	Levothyroxine Sodium	35	14
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	34	15
Jardiance	Empagliflozin	31	17
Bupropion Xl	Bupropion Hcl	29	14
Diclofenac Sodium	Diclofenac Sodium	29	14
Hydroxyzine Hcl	Hydroxyzine Hcl	28	17
Alprazolam	Alprazolam	27	11
Celecoxib	Celecoxib	27	19
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	26	suppressed
Nifedipine Er	Nifedipine	26	12
Olmesartan Medoxomil	Olmesartan Medoxomil	26	14
Venlafaxine Hcl Er	Venlafaxine Hcl	26	13
Zolpidem Tartrate	Zolpidem Tartrate	26	14
Clonidine Hcl	Clonidine Hcl	25	suppressed
Buspirone Hcl	Buspirone Hcl	24	12
Januvia	Sitagliptin Phosphate	24	11
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	24	18
Xarelto	Rivaroxaban	24	13
Spironolactone	Spironolactone	22	12
Chlorthalidone	Chlorthalidone	21	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	21	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	21	suppressed
Warfarin Sodium	Warfarin Sodium	21	suppressed
Mometasone Furoate	Mometasone Furoate	20	suppressed
Valsartan	Valsartan	20	11
Cephalexin	Cephalexin	19	14
Glimepiride	Glimepiride	19	12
Irbesartan	Irbesartan	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	19	suppressed
Lorazepam	Lorazepam	19	16
Myrbetriq	Mirabegron	19	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	18	suppressed
Terazosin Hcl	Terazosin Hcl	18	suppressed
Baclofen	Baclofen	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Hydrocortisone	Hydrocortisone	16	suppressed
Levetiracetam	Levetiracetam	16	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	16	suppressed
Humalog Kwikpen U-100	Insulin Lispro	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Symbicort	Budesonide/Formoterol Fumarate	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Benazepril Hcl	Benazepril Hcl	14	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	14	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	14	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Naproxen	Naproxen	13	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	12	suppressed
Carbamazepine	Carbamazepine	12	suppressed
Digoxin	Digoxin	12	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	12	suppressed
Propranolol Hcl	Propranolol Hcl	12	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	12	suppressed
Tresiba Flextouch U-200	Insulin Degludec	12	suppressed
Trulicity	Dulaglutide	12	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Glipizide-Metformin	Glipizide/Metformin Hcl	11	suppressed
Labetalol Hcl	Labetalol Hcl	11	suppressed
Memantine Hcl	Memantine Hcl	11	suppressed
Ondansetron Odt	Ondansetron	11	suppressed
Repaglinide	Repaglinide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error